AstraZeneca Plc has shaken up its pharma R&D structure, creating two units with parallel commercial operations whose heads will both report directly to the chief executive, Pascal Soriot
An oncology unit will be led by José Baselga, previously physician-in-chief at the Memorial Sloan Kettering Cancer Center in New York, US, while a unit for biopharmaceuticals, covering cardiovascular, renal, metabolic and respiratory medicines, will be headed by Mene Pangalos, a current AstraZeneca executive.